Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458526 | 0.90 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6008552 | 0.90 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6008097 | 0.90 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6007326 | 0.90 | CCR5 (1.00) | CCR5 | |
| SCHEMBL4458656 | 0.87 | CCR5 (0.81) | CCR5KCNH2CHRM2 | |
| SCHEMBL6007479 | 0.87 | CCR5 (0.81) | CCR5KCNH2 | |
| SCHEMBL6006922 | 0.86 | CCR5 (0.93) | CCR5 | |
| SCHEMBL6007297 | 0.86 | CCR5 (0.82) | CCR5 | |
| SCHEMBL6005856 | 0.86 | CCR5 (0.91) | CCR5 | |
| SCHEMBL6005984 | 0.85 | CCR5 (0.86) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| EP-1716156-A2 | CHEMOKINE CCR5 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075484-A2 | CHEMOKINE CCR5 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| US-20050176703-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CCR5 1/4885KCNH2 3129/4885CHRM2 3508/4885 |
| US-20050176703-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CCR5 1/4885KCNH2 3129/4885CHRM2 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.